Granules India Limited (GRANULES.BO)
Granules India Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hyderabad, TS, IN. The stock last traded at $858.10, up 0.08% on the session, giving a market capitalisation of $213.64B. Its beta of -0.02 implies it has historically moved less than the broad market.
Granules India Limited is a pharmaceutical firm specializing in the creation and distribution of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosage forms (FDs). Its global reach extends across numerous regions, including India, North America, Europe, Latin America, Africa, and the Middle East. The company's extensive portfolio of APIs addresses diverse therapeutic needs, encompassing treatments for conditions such as HIV (anti-retrovirals), high blood pressure (anti-hypertensives), allergies (anti-histamines), various infections (anti-infectives), pain management (analgesics), and blood-related issues (anti-coagulants, anti-fibriotics, and platelet inhibitors). Beyond APIs, Granules India also provides a variety of finished dosage forms, including tablets, caplets, and press-fit capsules. These are offered in formats suitable for bulk distribution, blister packaging, and bottles. Additionally, the company develops specialized products targeting oncology. Established in 1984, Granules India Limited is headquartered in Hyderabad, India.
Granules India Limited is most often compared with the following Healthcare names: